Why did Eli Lilly (LLY) stock move recently?

On 6/26/2026, Eli Lilly moved +7.1% — Eli Lilly shares rose sharply after the European Medicines Agency's CHMP issued a positive opinion recommending expanded approval of its oncology drug Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia across all lines of therapy. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Eli Lilly (LLY) overvalued or fairly valued?

MarketChacha shows Eli Lilly's valuation in context — a trailing P/E of about 48.2, a forward P/E of about 25.5, a price-to-book of about 32.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Eli Lilly's reported profit turn into cash?

Over 3 years, about 82% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement. MarketChacha computes this cash-conversion check (0.82×) from reported figures — education, not a rating.

What is Eli Lilly's revenue?

Eli Lilly reported revenue of $65.2B for FY2025, with net profit of $20.6B, per official filings.

What is the share price of Eli Lilly (LLY)?

Eli Lilly last traded at $1,148.84 (-0.5% on the day), as of 7/31/2026 — a delayed quote shown for education, not investment advice.

Eli Lilly

LLY · NYSE · Pharma · United States

Snapshot

TickerLLY

ExchangeNYSE

SectorPharma

IndustryDrug Manufacturers - General

CountryUnited States

Employees50,000

HeadquartersIndianapolis, United States

Websitewww.lilly.com

Filings tracked12

About Eli Lilly

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Who owns it

Insiders0.2%
Institutions85.1%
Public & other14.8%

5,685 institutional holders

Ownership breakdown from public market data.

Top holders

Lilly Endowment, Inc9.60%
Blackrock Inc.7.05%
Vanguard Capital Management LLC5.67%
PNC Financial Services Group, Inc.5.45%
State Street Corporation3.78%
FMR, LLC2.80%
Capital Research Global Investors2.62%
Vanguard Portfolio Management LLC2.23%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years, about 82% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement.

Cash conversion0.82×

Over 3 years, about 82% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement.

Net margin trend15.4% → 31.7%

Margin has expanded by about 16.3 points — the business is getting more profitable.

Return on equity77.8%

Latest ROE of 77.8% — capital is generating a healthy return.

Growth qualityrev 38% · PAT 98%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $21.7B · EPS 9.48

Est. earnings growth +35.0%

Next fiscal year

Rev $99.1B · EPS 45.08

Est. earnings growth +30.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$65.2B

Net margin

31.7%

ROE

77.8%

Revenue CAGR (2y)

+38.2%

Profit CAGR (2y)

+98.5%

EPS (FY2025)

22.95

Net profit (FY2025)

$20.6B

Ask MarketChacha about LLY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jun 26, 2026
Eli Lilly shares rose sharply after the European Medicines Agency's CHMP issued a positive opinion recommending expanded approval of its oncology drug Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia across all lines of therapy.
source 1 ↗source 2 ↗source 3 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about LLY

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$65.2B	$20.6B	22.95	31.7%	77.8%
FY2024	$45.0B	$10.6B	11.71	23.5%	74.2%
FY2023	$34.1B	$5.2B	5.80	15.4%	48.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$19.8B	$7.4B	8.26	37.4%
2025Q3	$17.6B	$5.6B	6.21	31.7%
2025Q2	$15.6B	$5.7B	6.29	36.4%
2025Q1	$12.7B	$2.8B	3.06	21.7%
2024Q3	$11.4B	$970.3M	1.07	8.5%
2024Q2	$11.3B	$3.0B	3.28	26.3%
2024Q1	$8.8B	$2.2B	2.48	25.6%
2023Q3	$9.5B	$-57.4M	-0.06	-0.6%
2023Q2	$8.3B	$1.8B	1.95	21.2%
2023Q1	$7.0B	$1.3B	1.49	19.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events, Exhibits
SEC5/20/2026material
8-K — Shareholder vote results
SEC5/7/2026material
8-K — Results of operations, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
10-K filing
SEC2/12/2026
8-K — Results of operations, Exhibits
SEC2/4/2026material

2025

8-K — Executive/director change
SEC11/21/2025material
8-K — Results of operations, Exhibits
SEC10/30/2025material
10-Q filing
SEC10/30/2025
8-K — Other events, Exhibits
SEC8/20/2025material
8-K — Results of operations, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.